GlycoMimetics Inc (Nasdaq:GLYC)
December 6th, 2018
GlycoMimetics Inc fell $0.37 Thursday which equals a 3.29% decline, closing at $10.87. As well as the drop in value, GlycoMimetics Inc hit a new 52 week low of $10.60.
GLYC was outperformed by the rest of the Healthcare sector which went down just 0.31%.
The market sectors were mixed Thursday with a majority of the sectors trending down. Real Estate saw the biggest increase of the day (2.66%), while Energy saw the biggest drop (1.77%). Healthcare has seen the biggest year-to-date gain at 12%. The biggest loss this year has been the Materials sector declining 12%.
Communication Services saw the biggest turnaround from its 5-day performance of -1.28%, as it went up 1.04%. Utilities saw a turn around from its 5-day performance of 2.33% trading down 0.10%.
- Real Estate went up with a 2.66% change.
- Communication Services went up with a 1.04% change.
- Consumer Discretionary went up with a 0.61% change.
- Information Technology went up with a 0.23% change.
- Utilities went down with a -0.10% change.
- Consumer Staples went down with a -0.10% change.
- Healthcare went down with a -0.31% change.
- Industrials went down with a -0.55% change.
- Materials went down with a -1.36% change.
- Financials went down with a -1.44% change.
- Energy went down with a -1.77% change.
GlycoMimetics Inc Info
GlycoMimetics, Inc., a clinical stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. Its advanced drug candidate, rivipansel, is a pan-selectin antagonist, which is developed for the treatment of vaso-occlusive crisis in sickle cell disease and has evaluated in a Phase 3 clinical trial, conducted by its strategic collaboration with Pfizer Inc. The company’s drug candidate, GMI-1271, an E-selectin antagonist, is evaluated in a Phase 1/2 clinical trial as a potential treatment for acute myeloid leukemia and is in a Phase 1 clinical trial for the treatment of multiple myeloma. It is also developing a Phase 1 clinical trial drug candidate, GMI-1359, a combined CXCR4 and E-selectin antagonist. It has a cooperative research and development agreement with the National Cancer Institute. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.
All amounts in USD unless otherwise indicated
Media Gazelle Inc (MG), a Nevada Corporation, owns and operates the online brand US Tribune News. MG does not offer financial advise, and is not a registered broker/dealer/analyst/adviser, holds no investment licenses, and may not sell, offer to sell or offer to buy any security. MG’s market updates, news are not a solicitation or recommendation to buy, sell or hold securities. MG shall not be held liable for any investment losses you may incur by using the information provided, this includes you trading the stocks mentioned on our sites. We recommend you talk to a financial adviser before trading any securities or taking any action based upon information on this site. MG does not guarantee the accuracy of the article.